** BMO Capital Markets raises its price target on AbbVie ABBV.N to $300 from $258, maintains its "outperform" rating

** Says continued strength in blockbuster immunology drugs Skyrizi and Rinvoq supports its positive view on the drugmaker despite emerging competition from newly launched therapies

** Expects Skyrizi sales to remain resilient, citing its efficacy, psoriatic arthritis approval and less-frequent dosing schedule

** The new price target represents a ~21% upside to the stock's last close

** For aesthetics business, BMO says macroeconomic pressures and shifting consumer preferences toward a more natural look continue to weigh on dermal filler brand Juvederm

** More upbeat on Botox Cosmetic, citing seasonal demand, higher tax refunds and increased use of GLP-1 weight-loss medicines

** Expects AbbVie to report Q2 revenue of $16.83 billion, slightly above consensus, but earnings per share of $3.59, below consensus due to a recently disclosed R&D-related charge

** Twenty-six of 33 brokerages rate the stock "buy" or higher, 7 "hold"; their median PT is $263 - LSEG data

** As of last close, stock up 8.6% YTD